Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14625407 | 1.00 | MAPT (0.38) | MAPTARLMNATSHRALDH1A1 | |
| SCHEMBL8789437 | 1.00 | MAPT (0.38) | MAPTARLMNATSHRALDH1A1 | |
| SCHEMBL7621446 | 1.00 | MAPT (0.38) | MAPTARLMNATSHRALDH1A1 | |
| SCHEMBL258503 | 1.00 | MAPT (0.38) | MAPTARLMNATSHRALDH1A1 | |
| SCHEMBL7621444 | 1.00 | MAPT (0.38) | MAPTARLMNATSHRALDH1A1 | |
| SCHEMBL6503043 | 1.00 | MAPT (0.38) | MAPTARLMNATSHRALDH1A1 | |
| SCHEMBL10925441 | 0.98 | MAPT (0.41) | MAPTARLMNATSHRALDH1A1 | |
| SCHEMBL2789219 | 0.95 | — | — | |
| SCHEMBL27274192 | 0.95 | — | — | |
| SCHEMBL25768512 | 0.86 | AR (0.33) | ARCDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005030719-A1 | NOVEL METHOD FOR PREPARING CIS-OCTAHYDRO-ISOINDOLE | LES LABORATOIRES SERVIER (FR) | 2005-04-07 | — | — | WO | claimed |
| US-20150216861-A1 | CYCLOPROPYL AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2015-08-06 | — | — | US | disclosed |
| US-9029381-B2 | Cyclopropyl amide derivatives | ASTRAZENECA AB (SE) | 2015-05-12 | — | — | US | disclosed |
| US-20120065193-A1 | Cyclopropyl Amide Derivatives '978 | ASTRAZENECA AB (SE) | 2012-03-15 | — | — | US | disclosed |
| WO-2011162562-A2 | [6+5] FUSED BICYCLES AS A THROMBIN ANTAGONIST, PROCESS FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE BICYCLES | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2011-12-29 | — | — | WO | disclosed |
| US-8063215-B2 | Cyclopropyl amide derivatives | ASTRAZENECA AB (SE) | 2011-11-22 | — | — | US | disclosed |
| US-20090076020-A1 | Cyclopropyl Amide Derivatives 978 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-7414056-B2 | Pyrazole-amide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-19 | — | — | US | disclosed |
| US-7405213-B2 | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| US-7253170-B2 | Pyrazole-amine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253167-B2 | Tricyclic-heteroaryl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-07 | — | — | US | disclosed |
| US-20070004733-A1 | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-04 | — | — | US | disclosed |
| WO-2005030719-A1 | NOVEL METHOD FOR PREPARING CIS-OCTAHYDRO-ISOINDOLE | LES LABORATOIRES SERVIER (FR) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030718-A1 | NOVEL METHOD OF PREPARING CIS-OCTAHYDRO-ISOINDOLE | LES LABORATOIRES SERVIER (FR) | 2005-04-07 | — | — | WO | disclosed |
| EP-0213506-A1 | Saturated cycloalkyl[c]pyrrole-2(1H)-acetic acid amides and derivatives thereof | WARNER-LAMBERT COMPANY (US) | 1987-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216861-A1 | CYCLOPROPYL AMIDE DERIVATIVES | HRH4, HRH2, HRH3 | MAPT 1670/4885AR 1269/4885LMNA 4640/4885 |
| US-20070004733-A1 | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith | MAP3K20, PRKDC, MAP3K2 | MAPT 956/4885AR 4180/4885LMNA 2351/4885 |
| US-20090076020-A1 | Cyclopropyl Amide Derivatives 978 | HRH4, HRH2, HRH3 | MAPT 1618/4885AR 1106/4885LMNA 4612/4885 |
| US-20120065193-A1 | Cyclopropyl Amide Derivatives '978 | HRH2, HRH4, HRH3 | MAPT 1361/4885AR 842/4885LMNA 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.